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ABSTRACT 
 
 
 
 
Small Molecule Inhibitors of MAPK and PI3K Pathways Enhance MDA-7 Lethality in 
Renal Cell Carcinoma 
 
By: Patrick John Eulitt 
 
A thesis submitted in partial fulfillment of the requirements for the degree of  
Master of Science at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2010 
 
Major Director: Dr. Paul Dent, Vice Chair of Research, Department of Neuro-Oncology 
 
 
Renal cell carcinoma accounted for an estimated 57,760 new cases and estimated 12,980 
deaths in the United States in 2009.  Current treatment options for systemic renal cell 
carcinoma yield markedly low response percentages; however, recent cytokine therapy 
experiments have produced promising results.  A novel adenovirus, Ad.5/3-mda-7, has 
been synthesized to efficiently infect renal cancer cells with the mda-7 gene.  This gene 
encodes for the cytokine MDA-7/IL-24 that has the ability to specifically target 
transformed cells.  Assays performed with this adenovirus resulted in an increased 
percentage of cell death in renal cancer cells when compared to infection with Ad.5/3-
cmv empty vector.  Further assays that combined Ad.5/3-mda-7 infection with treatments 
of small molecule inhibitors increased the percentages of cell death by upregulating JNK 
and p38 MAPK pathways, downregulating the ERK1/2 MAPK pathway, and 
downregulating the PI3K pathway.  Western blots confirmed upregulation and 
downregulation of these pathways by probing for key proteins.  Renal cancer cells 
responded best to infection with Ad.5/3-mda-7 and treatment with PD184352, PX866, 
  
and Rapamycin.  This combinatorial treatment caused a greater percentage of cell death 
than the sum of the two individual treatments, suggesting a synergistic inhibition of cell 
growth pathways.  These findings suggest that the combination of Ad.5/3-mda-7 and 
specific small molecule inhibitors has developmental potential as a novel and more 
efficient treatment option for systemic renal cell carcinoma. 
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CHAPTER ONE: 
INTRODUCTION 
 
1.1 Background 
Cancer is a major cause of death worldwide.  In the United States alone, a total of 
562,340 deaths from cancer were projected to occur in 2009.  Cancer still accounts for 
more deaths than heart disease in persons younger than 85 years of age, despite recent 
reductions in mortality and improvement of survival (Ahmedin et al. 2009).  Renal cell 
carcinoma (RCC) is the eighth most commonly diagnosed cancer in the United States, 
accounting for an estimated 57,760 new cases and estimated 12,980 deaths in 2009 
(Cersosimo, 2009).   
 
Treatment options for RCC have been relatively limited in the past; RCC has been shown 
to respond poorly to cytotoxic chemotherapy, and previous cytokine immunotherapy only 
produces moderate activity for the significant resulting toxicity (Saylor et al. 2009).  In 
recent years, new therapies have emerged including melanoma differentiation-associated 
7 (interleukin-24) and treatment with small molecule inhibitors (Yacoub et al. 2003, 
Kapoor et al. 2009).   
 
To develop novel therapies to combat the growth of tumor cells in RCC, numerous 
signaling pathways are currently being investigated.  The primary goal of these pathways 
is to increase apoptosis of cancer cells.  Apoptosis, also known as programmed cell death, 
is the most common mechanism used by the human body to eliminate unneeded or 
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damaged cells without the undesired effects of inflammation or cell leakage (Bree et al. 
2002). Cell necrosis, the passive mode of cell death, does share certain characteristics 
with apoptosis, but two processes are morphologically and biochemically distinct.  
Apoptosis is characterized by cell shrinkage, membrane blebbing without loss of integrity, 
and chromatin condensation with non-random DNA fragmentation (Ziegler et al. 2004).  
Cells undergoing necrosis, however, exhibit cell swelling, loss of membrane integrity, 
and random degradation of DNA (Ziegler et al. 2004). 
 
Apoptosis is regulated by many different cytoplasmic proteins and transcription factors, 
but all pathways require the activation of effector caspases which destroy vital proteins 
necessary for cellular survival (Lavrik et al. 2005).  The two main signaling pathways 
leading to apoptosis are the intrinsic and extrinsic pathways.   
 
The intrinsic pathway, also referred to as the mitochondrial pathway, is activated 
primarily in response to internal signals such as DNA damage.  This stimulates the tumor 
suppressor protein p53, which activates pro-apoptotic proteins that, in turn, activate 
caspase proteins in the mitochondria (Hengartner 2000).  Under normal conditions, anti-
apoptotic proteins, such as Bcl-2 and Bcl-XL, maintain the fidelity of the mitochondrial 
membrane by inhibiting the pro-apoptotic proteins, including BAX, BAK, and BAD 
(Hengartner 2000).  Under stressed conditions, p53 activates the pro-apoptotic proteins 
causing mitochondrial membrane permeabilization and subsequent release of cytochrome 
c and SMAC/Diablo (Henry-Mowatt et al. 2004).  Cytochrome c then binds to the 
apoptotic protease activating factor-1 (Apaf-1) and caspase-9 to form the aposome which 
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is able to activate the downstream caspases 3, 6, and 7 (Henry-Mowatt et al. 2004).  For a 
visual representation of this pathway, see Figure 1 below. 
 
The extrinsic pathway, as the name suggests, begins outside of the cell with the activation 
of pro-apoptotic receptors on the cell surface which are activated by specific molecules.  
One example of these receptor/ligand interactions is CD95L/FasL binding to CD95/Fas 
(Fulda et al. 2006). Other well characterized death receptors include TNF-related 
apoptosis-inducing ligand-receptor 1 (TRAIL-R1), TRAIL-R2, and TNF receptor 1 
(Fulda et al. 2006).  When the ligand binds to the appropriate receptor, there is induced 
receptor clustering which brings the adaptor protein Fas-associated death domain (FADD) 
to the activated receptor, which in turn recruits caspase-8 (Fulda et al. 2006).  This 
aggregate cluster is better known as the death inducing signaling complex (DISC) 
(Kischkel et al. 1995).  Pro-caspase molecules then migrate towards the DISC where they 
are processed and can activate effector caspases 3, 6, and 7 (Fulda et al. 2006).  These 
caspases then proceed to destroy cellular proteins vital for survival, effectively killing the 
cell.  This pathway can be visualized in Figure 2 below. 
 
Mitogen Activated Protein Kinase (MAPK) pathways are also excellent targets for 
regulation of cell survival, particularly the ERK1/2, JNK1/2 and p38 modules (Boldt et al. 
2002).  In general, MAPK pathways work via three core kinases: a MAPKKK activates a 
MAPKK, which activates a MAPK.  JNK and p38 are both the MAPK of their respective 
modules and after activation from cellular stress can signal the cell to undergo apoptosis.  
ERK1/2 is the MAPK of its module and signals for growth differentiation and 
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development.  After receiving developmental cues from growth factors, ERK1/2 can 
promote cell differentiation (Boldt et al. 2002, Dent et al. 2009).  The PI3K pathway 
functions to regulate cell growth in a similar manner to the ERK1/2 MAPK module, 
although it is morphologically distinct from the MAPK cascades (Dent et al. 2009).  
These 3 MAPK pathways, in addition to the PI3K pathway, are shown in Figure 3 below.   
 
Another physiological response that can lead to cell death is the ER stress response, 
which is caused by an accumulation of misfolded or unfolded proteins accumulating in 
the ER.  This aggregation of unfolded proteins is toxic to cells; therefore, these unfolded 
proteins trigger the unfolded protein response, which increase the folding capacity, 
inhibit protein translation and promote degradation of misfolded proteins (Hosoi et al. 
2010).  ER stress related signal transduction, which is shown in Figure 4, will lead to 
apoptosis via inhibition of anti-apoptotic proteins and activation of the JNK MAPK 
pathway (Hosoi et al. 2010).  IRE1 is a transmembrane protein that signals in response to 
unfolded and misfolded proteins in the ER.  When activated, IRE1 forms a complex with 
ASK1 which phosphorylates JNK, causing an induction of cell death (Rasheva et al. 
2009).  PERK is another ER-resident protein that signals in response to ER stress; 
however, it is distinct from IRE1 in its signaling cascade.  PERK, when phosphorylated, 
will phosphorylate the α-subunit of eIF2, which promotes the translation of ATF4 (Hosoi 
et al. 2010).  This transcription factor activates the CHOP promoter in the nucleus, 
causing an increase in production of the CHOP protein. By inhibiting anti-apoptosis 
proteins such as BCL-XL, BCL-2, and MCL-1, CHOP can sensitize cells to ER stress 
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induced apoptosis (Rasheva et al. 2009).  Therefore, two discrete pathways can lead to 
cell death via ER stress.   
 
Past therapeutic approaches for RCC, including chemotherapy and radiotherapy have 
yielded strikingly low response percentages, often as low as 2-6% (Bleumer et al. 2003).  
The low response can be partially accounted for by the resistance of renal cancer cells to 
the drugs being dispensed.  Cytokine immunotherapy is currently being investigated to 
treat RCC with varied results (Herrmann et al. 2010).  One particularly successful 
cytokine being investigated, melanoma differentiation-associated gene-7/interleukin-24 
(MDA-7/IL-24), has been shown to inhibit the proliferation of renal carcinoma cells and 
promote cell death (Yacoub et al. 2003). 
 
The gene mda-7was first identified in 1995 using differentiation induction subtraction 
hybridization (DISH), a novel technique that identifies differentially expressed genes in 
proliferating cancer cells and non-proliferating cancer cells (Fisher et al. 2003).  Further 
experiments with this gene found little to no RNA products in differentiating cancer cells, 
elevated RNA expression in normal cells, and inducible expression in terminally 
differentiated cancer cells (Fisher et al. 2003).  The unique properties of this cytokine 
identified in later experiments include its ability to discriminate between cancer cells and 
normal cells, inhibit tumor growth, induce apoptosis, and provide bystander antitumor 
activity (Fisher 2005).   
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Experiments suggesting bystander antitumor activity of MDA-7/IL-24 began as early as 
2001, but no definitive in vivo evidence was published on this topic until 2005.  Human 
breast carcinoma cells were inoculated into both flanks of nude mice, but only the left 
tumor was injected with Ad.mda-7.  This injection resulted in tumor regression in the left 
side and a statistically significant regression in the right side tumor as well, confirming 
the “bystander” anti-tumor properties of the secreted MDA-7/IL-24 protein (Emdad et al. 
2009).   
 
Although mda-7 was first identified in melanocytes, this gene was quickly tested on a 
wide range of human tumor cells with marked success.  The most efficient method of 
infecting tumor cells with mda-7 is to construct an adenovirus to efficiently insert the 
gene into cells (Fisher et al. 2003).  Adenoviruses insert DNA into the host cell via 
coxsackievirus and adenovirus receptors (CAR).  Therefore, the recombinant type 5 
adenovirus to express mda-7/IL-24 (Ad.mda-7) was generated and proved to be an 
efficient method to insert mda-7/IL-24 into cancer cells (Fisher 2005).  Unlike most 
cancer cells, RCC cells were found to be resistant to type 5 adenoviruses due to their low 
expression of CAR (Yacoub et al. 2003).  A recent paper outlining the potential 
therapeutic benefits of MDA-7/IL-24 on RCC also noted the necessity of developing a 
modified adenovirus to infect kidney cancer cells at a location other than the CAR (Park 
et al. 2009).  Fortunately, the development of a chimeric adenovirus, Ad.5/3-mda-7, has 
recently been developed to treat prostate cancer cells which also have a low expression of 
CAR.  This new adenovirus targets the Ad.3 receptors in a CAR-independent manner to 
more efficiently transfer the DNA to prostate cancer cells and induce cell death (Dash et 
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al. 2010).  It has been hypothesized that Ad.5/3-mda-7 would also work to effectively 
infect kidney cancer cells, due to the Ad.3 receptor targeting instead of CAR receptor 
targeting.  
 
Multiple signal pathways regulate MDA-7/IL-24-induced apoptosis, one of which 
includes inducing the ER-stress response and downstream MAPK enzymes (Fisher 2005).  
Other pathways affected by MDA-7/IL-24 include the extrinsic and intrinsic pathways 
mediating programmed cell death (Fisher 2005).  More recent studies have determined 
the mechanism of MDA-7/IL-24-induced killing in renal carcinoma cells to be 
ceramide/CD95/PERK-dependent accompanied by strong activation of JNK1/2 and p38 
MAPK pathways (Park et al. 2009).  Although MDA-7/IL-24 has been shown to be 
successful in treating cancer cells, it has been suggested that combining MDA-7/IL-24 
with small molecule inhibitors would provide the most profound therapeutic effects 
(Fisher 2005). 
 
One such inhibitor, PD184352, was discovered in 1999 in an assay to identify small 
molecule inhibitors of the MAPK pathway (Sebolt-Leopold et al. 1999). This compound, 
shown below in Figure 5, was found to directly inhibit MEK1 which would decrease 
activation of the downstream kinase, ERK.  In vivo treatment with PD184352 has been 
shown to result in complete suppression of MAPK phosphorylation in tumors, suggesting 
that it would be a great candidate for a combinatorial treatment with MDA-7/IL-24 
(Sebolt-Leopold et al. 1999). 
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PI-103 is another small molecule inhibitor which was first synthesized in 2007 and has 
been found to have many beneficial effects in cancer therapy (Raynaud et al. 2007).  The 
molecular structure of PI-103 is shown below in Figure 5.  Unlike PD184352, PI-103 is a 
selective class I Phosphoinositide 3-kinase (PI3K) inhibitor which has been shown to 
inhibit the proliferation of cancer cells in vitro (Raynaud et al. 2007).  PI-103 has also 
been shown to inhibit the mammalian target of rapamycin (mTOR), which is responsible 
for activating anti-apoptotic proteins (Chaisuparat et al. 2008).  By inhibiting class I PI3K, 
PI-103 also significantly lowers the activation of AKT, which has been shown to halt the 
G1 cell cycle progression and increase apoptosis (Erhardt et al. 1996, Gao et al 2004).  
Due to its activation of apoptosis via AKT and mTOR inhibition, PI-103 could 
potentially augment cellular apoptosis when treated with MDA-7/IL-24.   
 
PX866, shown below in Figure 5, is a small molecule inhibitor which was first 
synthesized in 2004 along with 9 other similar drugs.  Like PI-103, PX866 inhibits PI3K 
and downstream cellular AKT which halts growth and increases apoptosis in affected 
cells (Ihle et al. 2004).  Additionally, PX866 has also been shown to have antitumor 
activity on colon cancer cells and has been hypothesized to have antitumor properties in 
other cancer cell lines (Ihle et al. 2004).  PX866 was also tested in combination with 
other drugs and was found to act in a synergistic manner to kill tumors, which leads to the 
possibility of using PX866 in combination with MDA-7/IL-24. 
 
Rapamycin is the last small molecule inhibitor that was tested in this project, and it can 
be seen below in Figure 5.  Rapamycin is often referred to as Sirolimus, its United States 
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Adopted Name-assigned generic name, but for the purposes of this project, the name 
rapamycin will be used.  Rapamycin was first isolated from a soil sample from Easter 
Island and was used as an antifungal agent prior to its use as an antitumor and 
immunosuppressive drug (Sehgal 2003).  The mechanism underlying its antitumor 
properties begins with its association with a family of binding proteins termed FKBPs.  
Once rapamycin and FKBPs have associated, the complex can then bind directly to 
mTOR and block its function (Sehgal 2003).  Inhibiting the function of mTOR causes 
downstream inhibition of AKT which leads to an arrested cell cycle and decreased cell 
growth.  Like the other small molecule inhibitors, rapamycin has been tested in 
combination with other drugs, such as 5-flurouracil and cyclophosphamide, leading to the 
hypothesis that it would work well with MDA-7/IL-24. 
 
A recent phase I clinical trial with Ad.mda-7 aimed to take knowledge of mda-7 from the 
bench into the clinic, and was considered a resounding success.  The translational work 
was designed to evaluate the efficacy of intratumoral injection of Ad.mda-7 in patients 
with advanced carcinoma (Emdad et al. 2009).  All twenty-eight patients that enrolled in 
the study tolerated the adenovirus injection, all tumors injected demonstrated MDA-7/IL-
24 protein expression and apoptosis induction, and nearly half of the patients showed a 
marked decrease in tumor size at the conclusion of the study (Emdad et al. 2009).  The 
most clinically significant responses were seen in patients that received repeat injections 
of Ad.mda-7, but combining Ad.mda-7 with other inhibitory agents has been suggested to 
further enhance antitumor activity of the virus (Emdad et al. 2009).   
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The case for combinatorial therapies for cancer patients stems from the inability to 
translate in vitro tumor suppression of single inhibitory agents into the clinic.  When 
single kinase inhibitory agents were tested in vivo, the treatments were no longer 
cytotoxic; instead the agents seemed to be cytostatic (Dent et al. 2009).  The concept of 
pathway crosstalk has recently been suggested as an explanation to this reduction in 
response; it is possible that when one pathway is inhibited, another pathway that elicits a 
similar response may be upregulated (Junttila et al. 2008).  Only a small minority of 
cancerous tumors have a single mutation causing the uncontrolled growth. Therefore, the 
current theory calls for targeting multiple signal pathways to provide a more profound 
response in tumor cells (Dent et al. 2009).   
 
1.2 Objectives 
The first objective of this project was to determine if the newly synthesized adenovirus 
Ad.5/3-mda-7 would efficiently infect and increase the percentage of cell death in renal 
cancer cells, represented by the A498 cell line.  A secondary objective was to determine 
the most efficient treatment of small molecule inhibitors to enhance the toxicity of 
Ad.5/3-mda-7 in renal cancer cells.  The final objective was to confirm the mechanisms 
by which the adenovirus and small molecule inhibitors increase cell death. 
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Figure 1 
 
 
Figure 1: Intrinsic pathway of apoptosis activation 
(Adapted from Hengartner 2000 and Henry-Mowatt et al. 2004) 
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Figure 2 
 
 
Figure 2: Extrinsic pathway of apoptosis activation 
(Adapted from Fulda et al. 2006) 
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Figure 3 
 
 
Figure 3: Summary of signal transduction pathways targeted  
via small molecule inhibitors and MDA-7/IL-24 
 
(Simplified version of Dent et al. 2009) 
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Figure 4 
 
 
Figure 4: ER stress related signal transduction pathways leading to apoptosis 
(Adapted from Rasheva et al. 2009 and Hosoi et al. 2010) 
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Figure 5 
 
 
 
 
 
PD184352 
(Sebolt-Leopold et al. 1999) 
 
 
 
 
 
 
 
PI-103 
(Raynaud et al. 2007) 
 
 
 
 
PX866 
(Ihle et al. 2004) 
 
 
 
 
 
Rapamycin 
(Sehgal 2003) 
 
 
 
 
Figure 5: Chemical structures of small molecule inhibitors of MAPK pathway 
(PD184352) and PI3K pathway (PI-103, PX866, and Rapamycin) 
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CHAPTER TWO: 
MATERIALS AND METHODS 
 
2.1 Materials 
Minimum Essential Medium Alpha (MEMα), penicillin-streptomycin, 0.25% trypsin-
EDTA, and secondary antibody anti-mouse IgG were purchased from Invitrogen Life 
Technologies, Inc. (Carlsbad, CA).  The composition of MEMα is shown below in Table 
1.  Anti-phospho-p38 MAP Kinase (43 kDa, 1:000, rabbit polyclonal), anti-phospho-
SAPK/JNK (46, 54 kDa, 1:000, rabbit polyclonal), anti-MCL-1 (40 kDa, 1:1000, rabbit 
polyclonal), anti-mTOR (289 kDa, 1:1000, rabbit polyclonal) and anti-phospho-mTOR 
(289 kDa, 1:1000, rabbit polyclonal) were obtained from Cell Signaling (Boston, MA).  
Anti-BAX (23 kDa, 1:000, mouse monoclonal), anti-phospho- Akt1/2 (60 kDa, 1:1000, 
rabbit polyclonal), anti-phospho-eIF2 α (38 kDa, 1:1000, rabbit polyclonal), anti-eIF2α 
(36 kDa, 1:1000, rabbit polyclonal), anti-phospho-ERK (42, 44 kDa, 1:1000, mouse 
monoclonal), anti-GAPDH (37 kDa, 1:000, mouse monoclonal), and anti-phosho-PERK 
(125 kDa, 1:1000, rabbit polyclonal) were obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA).  Secondary antibody anti-rabbit IgG was purchased from Rockland 
Immunochemicals (Gilbertsville, PA).   
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Table 1 
 
 
Table 1: Composition of MEMα used for cell culture.  Data taken from Invitrogen website: 
http://www.invitrogen.com/site/us/en/home/support/Product-Technical-
Resources/media_formulation.109.html  
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2.2 Cell Culture 
The human renal cell carcinoma cell line, A498, was purchased from American Type 
Culture Collection (Rockville, MD).  This cell line was cultured in MEMα (Invitrogen) 
supplemented with 10% (v/v) FBS (American Type Culture Collection, Manassas, VA) 
and 2% penicillin/streptomycin.  Media was filtered using a 500 mL SFCA filter unit 
(Fisher Scientific: Kalamazoo, MI) to remove any impurities.  Cells were incubated in a 
humidified atmosphere of 5% (v/v) CO2 at 37°C.  Cells were plated at a minimum 
density of 2 x 105 per cm2.  
 
2.3 Recombinant Adenovirus Vectors: in vitro infection 
The Ad.5/3-mda-7 and Ad.5/3-cmv empty vector control adenoviral vectors used for the 
following experiments were generously provided by Dr. Paul Fisher (Department of 
Human and Molecular Genetics, Virginia Commonwealth University).  The stock 
concentrations for the adenoviruses used were as follows: 
 Ad.5/3-mda-7    =  4.5 x 1012 pfu/mL  
 Ad.5/3-cmv empty vector =  2.15 x 1012 pfu/mL 
 
After cells were allowed to grow for 24 hours, the cells were then infected with either 
Ad.5/3-mda-7 or Ad.5/3-cmv empty vector to obtain a multiplicity of infection (M.O.I.) 
of 50. 
 M.O.I. = [(desired m.o.i)*(# of cells)]/(titer of virus) 
Prior to infection, the adenoviruses were diluted in serum-free MEMα.  The complete 
media was aspirated from the plates, and the diluted Ad.5/3-mda-7 or Ad.5/3-cmv empty 
vector was added.  The plates were then placed on a rocker for 4 hours at the same 
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atmosphere in which cells are incubated: 5% (v/v) CO2 at 37°C.  After the media with the 
virus was aspirated from the plates 4 hours after infection, fresh 10% (v/v) FBS MEMα 
was added and the plates were returned to the incubator. 
 
2.4 Treatment with PD184352, PI-103, PX866, and Rapamycin 
24 hours after infection with Ad.5/3-mda-7 or Ad.5/3-cmv empty vector, cells were given 
drug treatments to further increase cell death.  The four drugs used were: PD184352, PI-
103, PX866 and Rapamycin.  Some experiments called for combinations of drugs; these 
combinations were: PD184352+PI-103, PD184352+PX866, PD184352+Rapamycin, and 
PD184352+PX866+Rapamycin.  In order to treat the cells at the recommended dosages, 
the drugs first needed to be diluted in serum-free MEMα.  Once the drugs were diluted 
into 2 mL dolphin Eppendorf tubes, the tubes were placed on a vortex for 2 intervals of 
10 seconds.  Drugs were added to the plates in the appropriate concentrations with the 
pipette tips replaced after each dish.  Eppendorf tubes were placed on a vortex after 
treatment of 3 dishes to ensure consistency in drug treatments.  Drug information can be 
found below in Table 2.  
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Table 2 
 
 
Drug Original Stock Conc. Dilution Final Conc. 
PD184325 50mM 1:25000 2μM 
PI-103 10mM 1:20000 0.5μM 
PX866 1mM 1:4000 0.25μM 
Rapamycin 10mM 1:10000 1μM 
 
Table 2: Dilution information for drugs used in the following experiments 
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2.5 Cell Lysis  
 Cells were cultured in 60 mm dishes for 24 hours, after which they were infected 
with either Ad.5/3-mda-7 or Ad.5/3-cmv empty vector.  24 hours after infection, the cells 
were treated with the specified drug or drug combination.  After incubation for six hours, 
the media was aspirated from the dishes and the dishes were immediately placed on a bed 
of ice.  The cells were lysed in 200μL of 2x SDS blue sample buffer.  This buffer solution 
contained 125 mM Tris-Cl, 20% (v/v) glycerol, 10% (v/v) β-mercaptoethanol, 4% (v/v) 
sodium dodecyl sulfate, and 0.04% (v/v) bromophenol blue at a pH of 6.8.  The dishes 
were scraped with disposable cell lifters (Fisher Scientific) and the lysate was collected 
and placed into 2 mL dolphin Eppendorf tubes.  These samples were boiled at 100°C for 
10 minutes and immediately frozen at -30°C until ready to be used. 
 
2.6 Polyacrylamide Gel Electrophoresis and Western Blot Analysis 
To prepare a gel for gel electrophoresis, the following steps were taken.  The glass plates 
were washed, rinsed with 70% (v/v) ethanol, and allowed to dry.  Spacers were placed 
between the glass plates and single screw clamps were aligned to secure the plates and 
spacers in place.  Once the bottom of the plates and spacers were aligned with the bottom 
of the screw clamps and Parafilm was placed in the BioRad casting stand, the contraption 
was secured and tightened into the stand.  The resolving gel was prepared in accordance 
to the values in Table 3 in the following order: milli-Q water, 1.5 M Tris (pH 8.8), 40% 
acrylamide (Biorad), 10% (w/v) ammonium persulphate, and TEMED (Fisher Scientific, 
Suwannee, GA).  Once the resolving gel was poured between the glass plates, 1 mL of 
saturated isobutanol was added to each gel.  The concentration of acrylamide used varied 
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inversely with the molecular weight of the protein under investigation; if a high 
molecular weight protein was being analyzed, a low concentration of acrylamide was 
used to facilitate migration down the gel. 
 
One hour following the addition of the resolving gel, the saturated isobutanol was 
removed from the gel, which was then gently cleaned with distilled water and carefully 
dried with Whatman 3M paper.  The combs (either 15 well or 20 well) were then placed 
between the glass plates and the stacking gel was prepared in accordance to the values 
listed in Table 3 and poured over the resolving gel.  Any air bubbles that formed around 
the wells were removed by shaking the comb before the stacking gel started to solidify.   
 
One hour after the addition of the stacking gel, the combs were removed and the gel 
apparatus was assembled.  To do this, the gels were removed from the casting stand and 
locked into place on the Protean 2 Gel Holder (Bio-Rad).  1X SDS Running buffer was 
prepared (6.00g Tris-base, 28.80g glycine, 10mL 20% SDS, QS to 2L deionized water) 
and poured between the two sets of glass plates.  The Gel Holder was allowed to sit for 
five minutes to inspect for leaks.  If the running buffer was leaking from the bottom of 
the gel, the screw clamps were tightened and the glass plates were inspected for cracks.  
Once the apparatus was determined to be leak free, it was placed in the gel case and the 
remaining running buffer was added until the case was about one-third full. 
 
The gel was then loaded with 75μL lysate and 25μL Dual Color Precision Plus Protein 
Standards (Bio-Rad) into the appropriate wells.  The gel apparatus was covered and 
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connected to a 200V power supply (Bio-Rad) and set to 475mA for two gels for about 5 
hours, or until the bromophenol blue dye front reached the bottom of the resolving gel. 
 
The next step in this process is transferring the protein from the gel to a 0.22μm 
nitrocellulose membrane (GE Water & Process Technologies).  In order to do so, it was 
first necessary to prepare the transfer solution, consisting of 9.09g Tris-base, 43.2g 
glycine, 15mL 20% SDS, 600mL methanol, and 2.1 L of deionized water.  This transfer 
solution was then degassed and allowed to cool at 4°C for two hours. 
 
Transfer solution was poured into 2 glass pans where the transfer cassette would be 
assembled.  A third glass pan was filled with deionized water.  A transfer cassette, 4 
pieces of Whatman 3M paper, 2 foam pads, and a sheet of nitrocellulose were gathered 
for each gel transfer.  The 0.22μm nitrocellulose membrane was placed in the water bath 
to check for uneven saturation.  If the membrane was evenly saturated, the nitrocellulose 
was transferred to the glass pan with the transfer buffer.  The items gathered were placed 
in the transfer cassette in the following order: one foam pad, two pieces of Whatman 3M 
paper, acrylamide gel, nitrocellulose membrane, two pieces of Whatman 3M paper, one 
foam pad.  Care was taken to ensure that there were no air pockets between the layers of 
materials, which would produce spots on the nitrocellulose membrane during 
development.  The locked transfer cassette was then placed in the transfer box so the 
current would run through the gel onto the nitrocellulose, and the transfer box was filled 
with the remaining transfer solution.  After connection to a 200V power source, the 
transfer box was set at 475mA for 5 hours. 
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Once 5 hours had passed, the transfer cassette was opened and the nitrocellulose was 
checked for the protein standards.  If the protein standards had transferred to the 
nitrocellulose membrane, it was assumed that the protein samples had also transferred to 
the membrane.  This nitrocellulose membrane was removed from the cassette, placed in a 
plastic container, and rinsed for 5 minutes with Tris Buffered Saline buffer (TBST): 
24.22g Tris-base, 18g NaCl, 1mL Tween 20 (Bio-Rad), QS to 1L deionized water.  After 
rinsing in TBST, the membrane was placed in a blocking buffer: 25g Blotting Grade 
Blocker Non-Fat Dry Milk (Bio-Rad), QS to 500mL TBST.  The membrane was kept in 
blocking buffer on a shaker for one hour at 4°C.  The primary antibody for the desired 
protein was then added to the blocking buffer in dilutions appropriate for the antibody 
(usually 1:1000) and was sealed with Saran wrap.  The covered nitrocellulose was kept 
on a shaker overnight at 4°C.   
 
The following day, the nitrocellulose was washed with TBST 3 times for 10 minutes to 
remove any non-specific primary antibody bonding.  Blocking buffer was then added to 
the nitrocellulose again, along with diluted secondary antibody to the specific mammal 
used for the primary antibody.  The nitrocellulose was then covered in Saran wrap and tin 
foil to prevent photobleaching of the secondary antibody, and kept at 4°C for one hour.  
After one hour, the nitrocellulose was washed 3 times for 10 minutes in TBST to remove 
any non-specific secondary antibody bonding and was read on the Odyssey Infrared 
Imager (Li-Cor) using Odyssey 2.1.  Images were then scanned and exported into Adobe 
Photoshop.   
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Table 3 
Solutions required for resolving gel for SDS-PAGE 
Resolving Gel One side Two sides 
 Components 50 mL 100 mL 
10% 40% acrylamide 12.5 25.5 
  1.5 M Tris (pH 8.8) 12.5 25 
  10% AP 0.5 1 
  TEMED 0.02 0.04 
  H2O 24.5 49 
12% 40% acrylamide 15 30 
  1.5 M Tris (pH 8.8) 12.5 25 
  10% AP 0.5 1 
  TEMED 0.02 0.04 
  H2O 22 44 
14% 40% acrylamide 17.5 35 
  1.5 M Tris (pH 8.8) 12.5 25 
  10% AP 0.5 1 
  TEMED 0.02 0.04 
  H2O 19.5 39 
 
Solutions required for resolving gel for SDS-PAGE 
Stacking Gel One side Two sides 
 Components 10 mL 20 mL 
5% 40% acrylamide 1.25 2.5 
  0.5 M Tris (pH 6.8) 2.5 5 
  10% AP 0.1 0.2 
  TEMED 0.01 0.02 
  H2O 6.2 12.4 
Table 3: Solutions required for the stacking and resolving gel for SDS-PAGE 
Only 10%, 12%, and 14% gels were used for this paper.  All volumes are in mL.  
H2O = milli-Q water, 10% AP= 10% (w/v) ammonium persulphate, TEMED (Fischer 
Scientific, Suwannee, GA) 
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2.7 Assessing Cell Death: Trypan Blue Exclusion Assay 
One method for evaluating the number of viable cells present in a cell suspension is to 
use a trypan blue exclusion assay.  Observed under light microscopy, viable cells with an 
intact membrane will exclude the trypan blue dye, whereas dead cells with a 
compromised membrane will include the dye.  To perform this assay, cells were plated in 
12-well plates with about 2 x 104 cells per well.  After 24 hours, the cells were infected as 
described above, and 24 hours after infection, cells were treated as described above.  At 
the specified time after treatment, the media was removed from each well and placed into 
a labeled 15mL tube.  185μL of trypsin was added to each well and the plates were 
incubated for 5 minutes.  500μL of PBS was then added to each well and the solution was 
mixed to ensure all the cells were in solution.  The cells and remaining solution were 
added to the appropriate 15mL tubes and these tubes were centrifuged at 1400 rpm for 4 
minutes.  The media was then aspirated and 75μL of trypan solution was added to each 
tube (1mL Trypan Blue (Sigma Aldrich), 9mL PBS).  The solution was mixed manually 
using a pipette for 2 minutes and loaded onto a hemocytometer.  Cells were counted on 
all four fields of the hemocytometer and the percentage of cells including trypan blue was 
determined for each tube.   
 
2.8 Statistical Analyses 
The effects of the drug treatments were analyzed using one-way ANOVA and Student’s 
t-test as a test for significance.  Differences with a p-value less than 0.05 were considered 
statistically significant.  Standard errors will be shown on the figures that follow.   
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CHAPTER THREE: 
RESULTS 
 
3.1 Infection with Ad.5/3-mda-7 causes greater cell death than infection with Ad.5/3-
cmv empty vector 
Cells that were infected with Ad.5/3-mda-7 had a higher percentage of cell death than 
cells that were infected with Ad.5/3-cmv empty vector, as assessed by trypan blue 
exclusion assay.  This proved that Ad.5/3-mda-7 was effective in infecting A498 renal 
cancer cell.  These results can be seen by comparing similar treatments between Ad.5/3-
mda-7 and Ad.5/3-cmv empty vector infections in Figure 6 and 7 below.  This supports 
past publications outlining the apoptosis inducing properties of MDA-7/IL-24 (Fisher et 
al. 2003, Fisher 2005). 
 
3.2 Treatment with small molecule inhibitors enhances Ad.5/3-mda-7 toxicity in 
RCC cells 
When combined with Ad.5/3-mda-7, small molecule inhibitors increase the percentage of 
cell death in A498 cells above the vehicle.  In Figures 6 and 7, nearly every treatment 
caused an increase in cell death, when compared to the vehicle.  Combinatorial treatment 
methods have not previously been attempted in A498 cells with Ad.5/3-mda-7 and these 
small molecule inhibitors, but the data suggest that a clinical trial may be warranted. 
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3.3 PD184352+PX866+Rapamycin provides greatest percentage of cell death, and 
treatment works synergistically with Ad.5/3-mda-7 
Of all the combinatorial treatments assessed in this project, the most effective treatment 
was PD184352+PX866+Rapamycin.  As seen in Figure 8, this treatment, combined with 
Ad.5/3-mda-7 produced the lowest ratio of cell survival when compared to combination 
with Ad.5/3-cmv empty vector.  Figure 9 offers a clearer depiction of the synergistic 
increased cell death caused by this treatment and Ad.5/3-mda-7 infection.  The empty 
vector adenovirus and the treatment caused about 20% cell death, and the mda-7 
adenovirus caused about 18% cell death. However, when Ad.5/3-mda-7 was combined 
with the treatment, there was greater than 50% cell death, suggesting a synergistic 
interaction between the virus and small molecule inhibitor combination. 
 
3.4 Western Blotting confirms ER stress induction, upregulation of JNK and p38 
MAPK signaling, and downregulation of ERK MAPK signaling by Ad.5/3-mda-7 
In a series of western blots, the Ad.5/3-mda-7 infection was confirmed to cause ER stress 
induction.  Figure 10 shows upregulation of P-PERK, P-eIF2α, and pro-apoptotic protein 
BAX in samples infected by Ad.5/3-mda-7 as compared to samples infected by Ad.5/3-
cmv empty vector.  When ER stress is induced, CHOP is synthesized downstream to 
inhibit protective anti-apoptotic proteins in the mitochondria, such as MCL-1, which is 
drastically downregulated by Ad.5/3-mda-7 in Figure 10 below.  All proteins measured in 
Figure 10 can be seen Figure 4, the ER stress related signal transduction pathway leading 
to apoptosis.   
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Ad.5/3-mda-7 also caused an upregulation of P-JNK and P-p38, both MAPK pathway 
proteins leading to apoptosis.  Figure 11 below shows the western blots that confirmed 
these upregulations, and Figure 3 shows the relationship of JNK and p-38 in the MAPK 
cascade. 
 
One pathway downregulated by Ad.5/3-mda-7 was the ERK MAPK pathway that results 
in cellular growth.  As seen in Figure 12, P-ERK1/2 expression is downregulated in 
samples infected with Ad.5/3-mda-7 when compared to samples infected with Ad.5/3-
cmv empty vector.  Figure 3 shows the relationship of ERK 1/2 in the MAPK cascade.  
GAPDH was used as a loading control in Figures 10 and 11. 
 
3.5 Western Blotting confirms inhibition of PI3K pathway by small molecule 
inhibitors  
Additional western blotting was performed to confirm the action of PI3K pathway 
inhibitors, including probing for P-mTOR, mTOR, and P-AKT.  Because Rapamycin 
inhibits mTOR, it was hypothesized that there would be a downregulation of P-mTOR, 
mTOR, and the downstream AKT, when compared to the vehicle.  PX866 is a PI3K 
inhibitor which would downregulate downstream P-mTOR, mTOR, and P-AKT, when 
compared to the vehicle.  All of these results can be seen in Figure 12 below.  GAPDH 
was used as a loading control in Figure 12.   
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Figure 6 
 
Figure 6: Infection with Ad.5/3-mda-7 causes greater cell death in A498 cells than 
infection with Ad.5/3-cmv as evaluated by a trypan blue exclusion assay.  Assay data are 
means of 3 wells (one column of 12 well plate per condition +/- SE) from representative 
experiment using different small molecule inhibitors and combinations of small molecule 
inhibitors (n=3).  PD=PD184352, PI=PI-103, PX=PX866 
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Figure 7 
 
Figure 7: Infection with Ad.5/3-mda-7 causes greater cell death in A498 cells than 
infection with Ad.5/3-cmv as evaluated by a trypan blue exclusion assay. Rapamycin was 
used in this assay instead of PI-103.  Assay data are means of 3 wells (one column of 12 
well plate per condition +/- SE) from representative experiment using different small 
molecule inhibitors and combinations of small molecule inhibitors (n=3).   
PD=PD184352, RAP=Rapamycin 
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Figure 8 
 
Figure 8: Ratio of cell survival (Ad.5/3-mda-7 infection + treatment: Ad.5/3-cmv 
infection + treatment) smallest with PD184352+PX866+Rapamycin. Data were generated 
from trypan exclusion assays, and normalized Ad.5/3-cmv + VEH to 1.0 survival.  Assay 
data are means of 3 wells (one column of 12 well plate per condition +/- SE) from 
representative experiment using different small molecule inhibitors and combinations of 
small molecule inhibitors (n=3). PD=PD184352, PX=PX866, RAP=Rapamycin 
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Figure 9 
 
Figure 9: Infection with Ad.5/3-mda-7, combined with treatment of 
PD184352+PX866+Rapamycin, was the most effective therapy for A498 RCC cells.  
Assay data are means of 3 wells (one column of 12 well plate per condition +/- SE) from 
representative experiment using different small molecule inhibitors and combinations of 
small molecule inhibitors (n=3). PD=PD184352, PX=PX866, Rap=Rapamycin 
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Figure 10 
 
 
 
Figure 10: Western blotting confirms ER stress induction by Ad.5/3-mda-7.  Cells were 
plated in 60 mm dish (2 x 105 cells/dish) and were infected with appropriate adenovirus 
24 hrs later.  Cells were treated with appropriate small molecule inhibitors 24 hrs after 
infection, and lysed 6 hrs after treatment.  Data are from a representative experiment 
(n=3). PD=PD184352, PX=PX866, Rap=Rapamycin 
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Figure 11 
 
 
 
 
 
Figure 11: Western blotting confirms upregulation of MAPK signaling by Ad.5/3-mda-7.  
Cells were plated in 60 mm dish (2 x 105 cells/dish) and were infected with appropriate 
adenovirus 24 hrs later.  Cells were treated with appropriate small molecule inhibitors 24 
hrs after infection, and lysed 6 hrs after treatment.  Data are from a representative 
experiment (n=3). PD=PD184352, PX=PX866, Rap=Rapamycin 
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Figure 12 
 
      
      
 
Figure 12: Small molecule inhibitors work to inhibit PI3K pathway.  Cells were plated in 
60 mm dish (2 x 105 cells/dish) and were infected with appropriate adenovirus 24 hrs 
later.  Cells were treated with appropriate small molecule inhibitors 24 hrs after infection, 
and lysed 6 hrs after treatment.  Data are from a representative experiment (n=3). 
PD=PD184352, PX=PX866, Rap=Rapamycin 
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CHAPTER FOUR: 
DISCUSSION 
 
4.1 Discussion 
Renal cell carcinoma has been shown to be resistant to traditional chemotherapy and 
produce low response rates to current radiation and chemotherapies, including IL-2 and 
IFN-α (Thompson 2009).  Prior to 2005, IL-2 and IFN-α were the only approved 
systemic therapies for RCC; however these cytokines only provided a clinical benefit for 
about 15% of RCC patients while causing significant systemic toxicity (Thompson 2009).   
 
The aim of this project was to investigate the response to the novel cytokine MDA-7/IL-
24 in RCC, due to its successful application to a wide spectrum of human cancer cells 
(Fisher 2005).  Additionally, this project studied the effect of small molecule inhibitors 
combined with the adenovirus delivery of mda-7.  The laboratory work performed 
throughout this project is designed to be a first step towards a clinical trial with these 
combinations, and the preliminary data support the transition from the bench to the clinic. 
 
Due to the recent synthesis of Ad.5/3-mda-7, expressing MDA-7/IL-24 in the cell has 
become much easier in cells lacking CAR.  Past experiments with Ad.mda-7 proved to be 
unable to alter RCC proliferation, which was determined to be the cause of a lack of CAR 
expression on RCC cells (Yacoub et al. 2003).  As was shown in Figure 6 and Figure 7, 
infection with Ad.5/3-mda-7 caused greater cell death than infection with Ad.5/3-cmv 
empty vector.  The mechanism of action was determined through a series of western blots 
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showing an upregulation of ER stress proteins coupled with an upregulation of MAPK 
proteins.  This suggests a dual action of MDA-7/IL-24: activation of the ER stress 
pathway, and upregulation of MAPK pathways leading to cell death. 
 
It was no surprise that RCC cells treated with both Ad.5/3-mda-7 and small molecule 
inhibitors would show an increased percentage of cell death; however, the combined 
effect suggesting a synergy between Ad.5/3-mda-7 and small molecule inhibitors was not 
expected.  The combinatorial treatment caused a greater percentage cell death than the 
sum of the two individual treatments.  This suggests that there is a significant amount of 
crosstalk between the MAPK pathways and potentially the PI3K pathway as well.   
 
The complexity of intracellular signaling has long been established. With the mounting 
number of signaling cascades and kinase pathways it would be unreasonable to presume 
that each pathway operates discretely.  For this reason, crosstalk, or signaling between 
pathways designed to elicit specific cellular responses, has been recently investigated in 
MAPK pathways as a potential explanation for decreased cellular growth (Junttila et al. 
2008).  There is evidence that both p38 signaling and JNK signaling is capable of 
inhibiting the ERK pathway of cellular growth, which could explain the downregulation 
of P-ERK in all Ad.5/3-mda-7 in Figure 12.  Crosstalk, combined with the synergy 
between the treatments that were observed, resulted in an increased percentage of cell 
death- especially in the Ad.5/3-mda-7 infection plus PD184352+PX866+Rapamycin 
treatment. 
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Although this treatment regimen was successful in killing A498 RCC cells in vitro, the 
next step would be to try these drug combinations in vivo.  If these same drug 
combinations (Ad.5/3-mda-7 with PD184352+PX866+Rapamycin) caused a decrease in 
tumor size in a mouse model, there would be sufficient evidence to warrant a clinical trial 
with MDA-7/IL-24 and these small molecule inhibitors. 
 
The goal of this project was to explore the ability of Ad.5/3-mda-7 to successfully infect 
RCC cells to increase cell death, and to test combinations of small molecule inhibitors to 
determine the most effective treatment.  From the data, it can be concluded that infection 
with Ad.5/3-mda-7 and treatment with PD184352+PX866+Rapamycin caused the most 
cell death in renal cancer cells.  This project provides evidence to support an in vivo trial, 
and potentially a clinical trial, due to the possibility that this regimen could be more 
effective in the treatment of renal cell carcinoma than current therapies. 
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